Category: Pharmaceuticals

Achillion Pharmaceuticals to Support a Natural History Study of C3…

Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London Natural history studies track course of a disease over time; can inform and support development and approval of new treatments for patients C3 glomerulopathy currently has no cure or approved treatment; affects about 8,000 people across Europe and the United States NEW HAVEN, Conn., Feb. 28, 2017 — Achillion Pharmaceuticals, Inc. announced that it has entered into an agreement with Imperial College London to conduct a natural history study of C3 glomerulopathy , a rare renal disorder which includes dense deposit disease and C3 glomerulonephritis .

Why GlaxoSmithKline’s 2017 Guidance Is Conservative

Assuming that Advair will face competition from a substitutable generic in the US by mid-2017, GSK guided for flat to a slight decline in Core EPS at constant exchange rates. The stock is trading at a discount to five years average historical P/E vs. peers and some potential source of earnings upside is expected in 2017.

Takeda and TiGenix Report New Data Highlighting Maintenance of…

Takeda Pharmaceutical Company Limited and TiGenix NV today announced new data from the Phase 3 ADMIRE-CD clinical trial, which indicated that investigational compound Cx601, a suspension of allogeneic adipose-derived stem cells , maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.[1] Results were presented at the 12th Congress of the European Crohn’s and Colitis Organisation .

President Akufo-Addo promises to support local Pharmaceuticals

President Nana Addo Dankwa Akufo-Addo on Friday said government was determined to support local pharmaceutical companies to manufacture anti-retroviral drugs for persons living with HIV and AIDS. He said the development of the country’s pharmaceutical industry, the production of drugs, particularly anti-retrovirals, was a key commitment of his government, and a part of a wider programme for the industrial growth of the country.

NANOBIOTIX appoints senior executive from pharmaceutical industry, as Chief Operating Officer

Paris, France and Cambridge, Massachusetts, USA, February 7, 2017 – NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer . Mr. Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for the Company’s lead product NBTXR3, which could obtain a CE Mark approval in 2017.

View Press Release

The Summit aims to showcase innovative organizations and how they are responding to changes occurring in the cancer care marketplace. “Today’s community oncology practices face many decisions and challenges, from new reimbursement structures to care models and technologies,” said Randy Hyun, senior vice president and general manager, Provider Solutions, McKesson Specialty Health.

Bristol-Myers Squibb stock sinks 7.2% after it says it won’t pursue…

The company said the decision was made “based on a review of the data available at this time,” and said it would say no more “in order to protect the integrity of ongoing registrational studies.” Leerink analyst Seamus Fernandez said the development was a “clear setback for BMY,” especially given a fall approval by rival drugmaker Merck in first-line lung cancer.

Mylan launches generic Zovia in U.S.

Mylan has announced the launch of a generic version of Zovia , a pregnancy preventative, in the U.S. The product — Ethyniol Diacetate and Ethinyl Estradiol tablets — was found to be bioequivalent to Zovia, and subsidiary Jai Pharma got FDA approval for its abbreviated new drug application.

Impax Laboratories Is Undervalued

Investors in the company have been let down time and again. Some factors for the continued weakness in shares include: A poor acquisition, whereby the company acquired a portfolio of generic drugs from Teva and Allergan for $586 million, only to then take an impairment charge of $285.2 million after failing to calculate the extent of the price reductions it would have to make on the products it acquired to retain key clients.